GALT vs KMI · $142.4M cap vs P/E 24, rev $9.30B
Galectin Therapeutics Inc (GALT) versus Kinder Morgan Inc (KMI) — a side-by-side from cached financials, not a winner call.
Galectin Therapeutics Inc (GALT) is a biotechnology company listed on US.
Kinder Morgan Inc (KMI) is a oil & gas midstream company listed on US.
GALT does not have a complete income-statement cache yet.
Latest reported KMI revenue for 2026-06-30 was $9.30B. Net income was $1.84B. Revenue was up 92.7% from 2026-03-31 to 2026-06-30. KMI currently screens at market cap $62.53B and trailing P/E 24.2.
GALT currently screens at market cap $142.4M. KMI currently screens at market cap $62.53B and trailing P/E 24.2.
Not investment advice. Open the GALT and KMI stock pages for the full models.
Not investment advice.